FinSMEs
Plexium Raises $102M Financing
Plexium
First Investment: 2018
Targeted protein degradation (TPD) is a way to inhibit or modulate the function of disease-causing proteins that aren’t druggable using conventional small molecules. Plexium is using a proprietary high-throughput cell screening technology to explore a variety of potential next-generation approaches to TPD, from monovalent protein degraders to molecular glues to novel E3 ligases. With partners, and on its own, the company is developing TPD drugs to fight cancer, central nervous system diseases, and other conditions.
Explore Companies
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster
Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs
Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery